IQIYI Inc - ADR vs Vaxcyte Inc. Common Stock — how do they compare? IQIYI Inc - ADR trades at $0.94 (market cap $918.03M), while Vaxcyte Inc. Common Stock trades at $67.27 (market cap $10.63B). The key difference: Vaxcyte Inc. Common Stock is far larger — about 11.6× IQIYI Inc - ADR's market cap, and Vaxcyte Inc. Common Stock is trading nearer its 52-week high, IQIYI Inc - ADR nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold IQIYI Inc - ADR for 55 Days and Vaxcyte Inc. Common Stock for 0 Days on average.
| IQ | PCVX | |
|---|---|---|
Market Cap | $918.03M | $10.63B |
Volume | 10,354,180 | 1,525,205 |
Sector | Media | Health |
52-Week High | $2.35 | $73.82 |
52-Week Low | $0.86 | $40.32 |
Typical Hold Time | 55 Days | 0 Days |
Enterprise Value | $2.41B | $9.26B |
Signals from Pluang's Aura AI — not financial advice
IQ trades at $0.99, down 2.78% today, with a neutral technical signal. The company reported a net loss of $206 million in 2025 despite beating EPS estimates in recent quarters. Revenue has declined from $31.9B in 2023 to $27.3B in 2025. Analyst sentiment is mixed with a 50% buy rating. Recent news highlights AI-driven content initiatives, including the successful 'The Ferry Man' series.
The outlook is cautious; while AI innovation offers growth potential, persistent revenue declines and negative margins pose risks. The stock's low P/S and P/B ratios suggest undervaluation, but profitability challenges and high debt levels require careful monitoring. Upside depends on successful execution of AI content strategy and return to revenue growth.
No Aura AI signal available yet.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
iQIYI Inc is an online entertainment service provider in China. It is primarily engaged in providing a variety of services encompassing internet video, live broadcasting, online games, online literature, animations, e-commerce, and social media platform. The company produces original video content and distributes appealing professionally produced content, partner-generated content, and user-generated content. It also offers a diverse collection of internet video content that appeals to users from broad demographics. The company's revenue is generated from membership services and online advertising services. The company earns most of its revenue from China.
Read more on IQ →Vaxcyte, Inc. is a clinical-stage vaccine company that engineers protein-based vaccines to prevent bacterial diseases such as invasive pneumococcal disease, using its proprietary cell-free protein synthesis platform to develop candidates including the pneumococcal conjugate vaccines VAX-31 and VAX-24.
Read more on PCVX →